Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

被引:116
作者
Anindita Chowdhury
Selvaraj Kunjiappan
Theivendren Panneerselvam
Balasubramanian Somasundaram
Chiranjib Bhattacharjee
机构
[1] Jadavpur University,Department of Chemical Engineering
[2] Kalasalingam University,Sir CV Raman
关键词
Degenerative diseases; Nanotechnology; Nanocarrier; Biocompatibility; Drug delivery; Drug resistance; Drug development; Bioavailability; Blood–brain barrier;
D O I
10.1007/s40089-017-0208-0
中图分类号
学科分类号
摘要
Degenerative diseases are results of deterioration of cells and tissues with aging either by unhealthy lifestyle or normal senescence. The degenerative disease likely affects central nervous system and cardiovascular system to a great extent. Certain medications and therapies have emerged for the treatment of degenerative diseases, but in most cases bearing with poor solubility, lower bioavailability, drug resistance, and incapability to cross the blood–brain barrier (BBB). Hence, it has to be overcome with conventional treatment system; in this connection, nanotechnology has gained a great deal of interest in recent years. Moreover, nanotechnology and nanocarrier-based approach drug delivery system could revolutionize the treatment of degenerative diseases by faster absorption of drug, targeted interaction at specific site, and its release in a controlled manner into human body with minimal side effects. The core objective of this review is to customize and formulate therapeutically active molecules with specific site of action and without affecting other organs and tissues to obtain effective result in the improvement of quality of health. In addition, the review provides a concise insight into the recent developments and applications of nanotech and nanocarrier-based drug delivery for the treatment of various degenerative diseases.
引用
收藏
页码:91 / 122
页数:31
相关论文
共 1095 条
[1]  
Murray CJ(1994)Global and regional cause-of-death patterns in 1990 Bull. World Health Organ. 72 447-247
[2]  
Lopez AD(2000)Oxidants, oxidative stress and the biology of ageing Nature 408 239-74
[3]  
Finkel T(2009)Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options Curr. Neuropharmacol. 7 65-156
[4]  
Holbrook NJ(2014)Nanocarrier-based approaches for treatment and detection of Alzheimer’s disease J. Nanosci. Nanotechnol. 14 137-1070
[5]  
Uttara B(2007)Nanotechnology-based drug delivery systems J. Occupat. Med. Toxicol. 2 16-302
[6]  
Singh AV(2010)Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 1067-135
[7]  
Zamboni P(2015)Stealth Amphotericin B nanoparticles for oral drug delivery: in vitro optimization Saudi Pharmac. J. 23 290-2842
[8]  
Mahajan RT(2002)PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties J. Control. Release 79 123-1060
[9]  
Oesterling BM(2013)A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel Biomaterials 34 2834-3474
[10]  
Gulati A(2013)Encapsulation of Ellipticine in poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) based nanoparticles and its in vitro application Mater. Sci. Eng. C 33 1054-394